Archives de la catégorie: ASCO Annual meeting

June 1 – 5th, 2012 / Chicago, USA

June 1 - 5th, 2012 / Chicago, USA First european phase II trial of intravenous (iv) cetuximab (Cet) and hepatic artery infusion (HAI) of irinotecan, 5-fluorouracil and oxaliplatin in patients with unresectable liver metastases from wt KRAS colorectal cancer (CRC) after systemic therapy failure (OPTILIV, NCT00852228). Levi F., Ducreux M.l, Hebbar M., Rougier P., Focan…
lire la suite

May 31st -June 4th 2013 / Chicago, USA

May 31st -June 4th 2013 / Chicago, USA Robustness of circadian rest-activity rhythm for predicting efficacy of intravenous cetuximab and hepatic artery infusion of chronomodulated irinotecan, 5-fluorouracil and oxaliplatin for liver metastases from colorectal cancer (Optiliv translational study, NCT00852228). Karaboué A., Innominato P., Bouchahda M., Mocquery M., Bossevot R., Plessis V., Bouchoucha D., Adam R.…
lire la suite

May 30th – June 3rd 2014 / Chicago, USA

- May 30th - June 3rd 2014 / Chicago, USA Constitutive Single Nucleotide Polymorphisms assessment for predicting tolerability and efficacy of triplet hepatic artery infusion and intravenous cetuximab in patients with liver metastases from colorectal cancer (European trial OPTILIV, NCT00852228). Lévi F., Karaboué A., Saffroy R., Peyric E., Ducreux M., Smith D., Hebbar H., Innominato…
lire la suite